introduction date different platform sars-cov-2 vaccine labelled emergency use authorization specifically mrna vaccine viral-vector vaccine protein subunit vaccine whole-cell inactivated virus vaccine vaccine shown immunogenicity efficacy effectiveness sars-cov-2 vaccine elicit humoral cellular immune response work together protect infection case sars-cov-2 infection postulated neutralizing antibody essential controlling sars-cov-2 infection effective clearance virus dependent cell however evidence suggest cell-mediated immunity able control covid-19 without substantial contribution neutralizing antibody vaccine including covid-19 vaccine believed protect disease neutralizing antibody due technical expertise requirement determining cell-mediated immune response detection humoral response achievable humoral immune response measured detection either binding antibody i.e immunoglobulin igg level anti-s spike protein anti-receptor-binding domain anti-rbd subunit neutralizing antibody detection test i.e gold-standard manual plaque reduction neutralization test prnt pseudotyped virus neutralization assay pna surrogate virus neutralization test svnt neutralizing antibody determines efficacy performance antibody prevent infection sars-cov-2 vitro currently recommendation generalized using antibody testing ass immunity sars-cov-2 covid-19 vaccination determine necessity vaccination unvaccinated individual requirement booster dose however antibody testing may applied occupational health public health research purpose neutralizing antibody detection tends acceptable predictor may used key marker vaccine efficacy clinical trial correlation shown level antibody protection symptomatic covid-19 disease due high cost available commercial kit developed in-house enzyme-linked immunosorbent assay elisa detection anti-s-igg antibody in-house neutralizing antibody test kit svnt current research purpose thus study conducted evaluate correlation among binding antibody assay i.e in-house elisa two commercial immunoassay elecsys anti-sars-cov-2 immunoassay roche diagnostics s-specific-igg-test sars-cov-2 igg quant assay abbott laboratory rbd-specific-igg-test serum vaccinated adult evaluate correlation neutralizing antibody test i.e sars-cov-2 neutralisa assay euroimmun commercial svnt in-house sars-cov-2 surrogate virus neutralization test in-house svnt identify level binding specific igg antibody correlated inhibition commercial svnt result participant previously received dos coronavac® vaccine patient 25.5 male median age iqr year specimen consisting sample third dose chadox1 ncov-19 vaccine sample third dose bnt162b2 mrna vaccine sample week third dose chadox1 ncov-19 vaccine sample week third dose bnt162b2 mrna vaccine total specimen analysed median iqr rbd-specific antibody s-specific binding antibody in-house s-specific binding antibody third dose vaccine 65.6 36.1 101.2 62.3 32.9 118.5 18.5 10.8 28.1 bau/ml respectively 1821.4 1096.7 2892.8 9213.2 5022.5 15330.6 467.2 392.1 539.4 bau/ml week third dose vaccine respectively median iqr inhibition commercial svnt in-house svnt 28.2 13.3 45.9 22.8 15.9 39.8 respectively third dose 99.5 99.1 99.7 98.5 98.2 98.6 week third dose respectively correlation among binding-specific igg antibody test correlation log scale rbd-specific-igg-test s-specific igg-test 0.97 0.96–0.98 fig s-specific-igg-test in-house elisa 0.96 0.96–0.97 fig rbd-specific-igg-test in-house elisa 0.96 0.95–0.97 fig figure correlation among binding-specific igg antibody test in-house sars-cov-2 surrogate neutralization test sars-cov-2 neutralisa full size image correlation in-house svnt commercial svnt correlation inhibition in-house svnt commercial svnt 0.91 0.87–0.94 -value 0.001 fig converting in-house svnt commercial svnt equation used inhibition in-house svnt 0.9779 inhibition commercial svnt 1.1068 another way alternative calculation inhibition commercial svnt inhibition in-house svnt 1.3587 optimal cut-off value binding specific igg antibody using commercial svnt reference standard cut-off level inhibition commercial svnt rbd-specific-igg-test designated 7.1 bau/ml cut-off level positive result agreement cohen kappa 0.04 sensitivity specificity s-specific-igg-test designated 0.8 bau/ml cut-off level positive result also agreement kappa sensitivity sequential step applied area roc auroc curve rbd-specific-igg-test s-specific-igg-test 0.99 0.97 respectively fig cut-off value rbd-specific-igg-test 83.9 bau/ml increased agreement kappa 0.91 sensitivity specificity respectively optimal cut-off value s-specific-igg-test 90.9 bau/ml using cut point agreement increased kappa 0.82 sensitivity specificity respectively table cut-off level inhibition commercial svnt figure receiver operating characteristic roc curve analysis binding-specific antibody inhibition sars-cov-2 neutralisa full size image table optimal cut-off value sars-cov-2 quant using sars-cov-2 neutralisa reference standard full size table table optimal cut-off value elecsys anti-sars cov-2 immunoassay using sars-cov-2 neutralisa reference standard full size table description based example inhibition rbd-specific-igg-test designated 7.1 bau/ml cut-off level positive result agreement kappa 0.02 0–0.04 sensitivity 98–100 specificity 0–6 s-specific-igg-test designated 0.8 bau/ml cut-off level positive result also agreement kappa sensitivity sequential step applied auroc curve rbd-specific-igg-test s-specific-igg-test respectively fig rbd-specific-igg-test agreement kappa 0.99 optimal cut-off value 442.7 bau/ml sensitivity specificity optimal cut-off value 1155.9 bau/ml s-specific-igg-test agreement kappa 0.99 sensitivity assay specificity optimal cut-off value agreement kappa sensitivity specificity inhibition shown table kappa in-house sars-cov-2 svnt commercial svnt cut-off level inhibition commercial svnt in-house svnt agreement 95.7 kappa 0.90 0.80 1.00 using commercial svnt reference standard sensitivity specificity in-house svnt 87–99 82–100 respectively discussion study demonstrated strong correlation among sars-cov-2 igg quant assay elecsys anti-sars-cov-2 immunoassay s-specific antibody in-house elisa correlation 0.95 several study reported moderate strong correlation commercially available immunoassay although correlation strong regard direction s-specific antibody elecsys anti-sars-cov-2 immunoassay higher level rbd-specific antibody detected sars-cov-2 igg quant assay 4-weeks third dose vaccination finding also reported perkmann al. found correlation elecsys anti-sars-cov-2 immunoassay abbott architect rbd-specific antibody different different time point vaccination emphasizes importance detailed interpretation result particularly different test different time point addition antibody in-house elisa lower level s-specific antibody elecsys anti-sars-cov-2 immunoassay rbd-specific antibody fig comparison commercial in-house technique detect antibody spike protein different method i.e eclia former elisa latter antibody level in-house elisa lower correlation weaker time point third dose similar finding found comparing antibody in-house elisa rbd-specific antibody case neutralizing antibody correlation in-house svnt commercial svnt also strong correlation 0.91 although scattered result away regression line 30–70 inhibition satisfactory result in-house elisa also in-house svnt commercially available test test may cost effective alternative way detecting antibody acceptable performance several study showed vaccine efficacy vaccine effectiveness correlated neutralizing antibody level protection symptomatic covid-19 infection protection severe disease required lower neutralizing antibody level conferring protection mild disease predictive model identifying mean neutralization titer relative convalescent correlate protective efficacy sars-cov-2 infection mostly due sars-cov-2 variant b.1.177 study predicted vaccine efficacy symptomatic infection level anti-spike igg anti-rbd igg normalized live-virus neutralization assay pseudovirus neutralization assay respectively example vaccine efficacy symptomatic covid-19 infection mostly b.117 variant sars-cov-2 achieved anti-spike igg 40,923 au/ml bau/ml anti-rbd-igg 63,383 au/ml bau/ml nf50 normalized live-virus neutralization assay id50 pseudovirus neutralization assay data compare vaccine efficacy inhibition svnt published study however correlation svnt virus neutralization test plaque-reduction neutralization test prnt reported cut-off level positive result sars-cov-2 igg quant assay elecsys anti-sars-cov-2 immunoassay demonstrated agreement cut-off level seroconversion commercial svnt sequential step applied optimal cut-off value sars-cov-2 igg quant assay elecsys anti-sars-cov-2 immunoassay inhibition commercial svnt 83.9 bau/ml 90.9 bau/ml respectively level 442.7 bau/ml sars-cov-2 igg quant assay 1155.9 bau/ml showed almost perfect agreement inhibition also performed test cut point inhibition result shown table sensitivity specificity reduced inhibition however result must interpreted caution assay tested wild-type sars-cov-2 variant kappa statistic in-house svnt commercial svnt almost perfect proposed equation switching however equation may suitable study population research purpose cost limited straightforward technical requirement lower operating cost determination binding-specific antibody level convenient evaluating immune response vaccination sars-cov-2 infection immunity infection furthermore long-acting antibody laab available use pre-exposure prevention covid-19 certain population antibody level may help guide selection eligible patient example department disease control ministry public health thailand suggested prescribing laab patient end-stage renal disease esrd kidney organ-transplant bone marrow transplant received immunosuppressive therapy esrd hemodialysis peritoneal dialysis received least dos vaccine sars-cov-2 anti-spike igg of/ comparable bau/ml first priority due imbalance certain population available laab study several limitation first binding specific antibody inhibition svnt tested wild-type sars-cov-2 virus major variant interest vois variant concern vocs required higher level antibody wild-type sars-cov-2 interpretation cut-off level study may applied current situation circulating virus vois vocs second reference standard used study svnt gold standard neutralizing antibody detection although correlation svnt prnt result must interpreted caution third although in-house svnt in-house elisa provide satisfactory result economic advantage compared commercial assay require overnight incubation ace-2 antigen elisa plate therefore take time complete assay compared ready use commercial kit conclusion study demonstrated strong correlation in-house elisa commercially assay available thailand i.e sars-cov-2 igg quant assay elecsys anti-sars-cov-2 immunoassay however testing binding specific antibody test must used longitudinal study antibody level test different fig also strong correlation in-house svnt commercial svnt great interest inform future research finding helpful research purpose save cost acceptable level outcome method cross-sectional study conducted maharaj nakorn chiang mai hospital tertiary care hospital affiliated chiang mai university september december comparison test left-over serum sample taken healthcare worker enrolled onto study immunogenicity sars-cov-2 vaccination provided written informed consent future study collected brief participant healthcare worker aged 18–60 year previously received dos coronavac® vaccine received third dose vaccine either chadox1 ncov-19 azd1222 bnt162b2 mrna serum participant week third dose vaccine selected serum separated test s-specific-igg-test rbd-specific-igg-test in-house elisa commercial svnt in-house svnt test performed wild-type sars-cov-2 virus laboratory assay binding antibody sars-cov-2 igg quant assay abbott laboratory inc usa automated two-step immunoassay designated qualitative semi-quantitative detection igg antibody sars-cov-2 human serum plasma using chemiluminescent microparticle immunoassay cmia technique amount antibody presented arbitrary unit assay measured concentration anti-rbd-wt wild-type igg level 40,000 au/ml value converted binding antibody unit bau multiplying 0.142 per recommendation cut-off level positive result au/ml 7.1 bau/ml elecsys anti-sars-cov-2 immunoassay roche diagnostics international ltd rotkreuz switzerland double-antigen sandwich major principle test reagent consists antigen predominantly captured anti‑sars‑cov‑2 igg also captured anti‑sars‑cov‑2 iga igm level determined electrochemiluminescence immunoassay eclia value presented u/ml assay measured concentration anti-s-wt wild-type igg level 0.4 u/ml sample anti‑sars‑cov‑2‑s concentration measurable range diluted diluent universal 1:100 dilution value converted bau/ multiplying 1.029 per recommendation cut-off level positive result 0.8 u/ml 0.8232 0.8 bau/ml determination specific s-binding igg antibody in-house elisa antibody specific spike protein determined indirect elisa fifty microliters µg/ml spike protein genscript piscataway usa bicarbonate buffer 9.6 added 96-well maxisorp immunoplates thermo scientific roskilde denmark incubation overnight plate washed washing buffer 0.05 tween-20 calbiochem gibbstown usa phosphate buffer saline blocked skimmed milk fifty microliters sample diluted ratio 1:100 serially diluted positive control added incubated washing goat anti-human igg conjugated horse radish peroxidase hrp invitrogen carlsbad usa added incubated washing tetramethylbenzidine tmb substrate life technology frederick usa added plate incubated room temperature min enzyme reaction terminated using 0.2 sulfuric acid absorbance read microplate reader clariostar® ortenberg germany antibody level determined standard curve derived serial dilution international standard anti-sars-cov-2 immunoglobulin nibsc assigned arbitrary unitage bau/ml theoretical curve single antibody antigen least-squares fit logit-transformed data model used calculate arbitrary unit sample described previously value presented bau/ml cut-off level seroconversion set time standard deviation negative test value 50.7 bau/ml neutralization assay sars-cov-2 neutralisa euroimmun medizinische labordiagnostika lübeck germany concept test intended mimic virus-host interaction utilizing recombinant rbd sars-cov-2 spike protein detect antibody block rbd binding hace2 receptor using established elisa method assay performed following manufacturer instruction value identified study presented percent inhibition cut-off level seroconversion in-house sars-cov-2 surrogate virus neutralization test in-house sars-cov-2 svnt in-house sars-cov-2 svnt modified method previously described tan brief well maxisorp immunoplates coated μg/ml ace2 genscript piscataway usa bicarbonate buffer overnight washing well blocked bovine serum albumin paa laboratory pasching austria incubated sixty microliters serum participant control diluted ratio 1:4 pre-incubated 1:200 hrp-rbd genscript min discarding blocking buffer sera-rbd-hrp mixture transferred plate incubated min washing tmb substrate solution added followed 0.2 sulfuric acid stopping solution min incubation period absorbance read using clariostar® microplate reader pooled convalescent serum patient aged 18–59-years old pcr-confirmed alpha delta sars-cov-2-variant infection admitted maharaj nakorn chiang mai hospital provided written informed consent used positive control pooled serum participant collected sars-cov-2 vaccination used negative control value presented percent inhibition cut-off level seroconversion determined mean inhibition individual negative serum plus standard deviation test performed wild-type sars-cov-2 statistical analysis sample size calculation sample size calculated based comparison s-specific-igg-test commercial svnt rbd-specific-igg-test commercial svnt required largest sample size study using expected kappa greater 0.8 e.g 0.9 probability positive result test 0.75 0.75 probability seroconversion test 0.7 respectively two-sided alpha 0.05 power sample required data analysis demographic data including age gender underlying disease described number mean median iqr appropriate correlation test continuous outcome i.e in-house elisa v.s s-specific-igg-test in-house elisa v.s rbd-specific-igg-test s-specific-igg-test v.s rbd-specific-igg-test log-transformed analyzed using pearson correlation coefficient correlation pearson correlation coefficient i.e in-house elisa v.s s-specific-igg-test in-house elisa v.s rbd-specific-igg-test s-specific-igg-test v.s rbd-specific-igg-test commercial svnt v.s in-house svnt analysed using spearman rank correlation coefficient correlation coefficient reported estimate value confidence interval correlation strength 0–0.09 0.10–0.29 0.30–0.59 0.60–0.79 0.80–0.99 defined none poor fair moderate strong perfect respectively scatterplot used describe direction form strength correlation used quantile regression model converting in-house svnt commercial svnt converting commercial svnt in-house svnt cohen kappa used measure agreement test binary outcome kappa value 0–0.20 0.21–0.39 0.40–0.59 0.60–0.79 0.80–0.90 0.90 defined minimal weak moderate strong almost perfect level agreement identify value binding specific igg antibody correlated inhibition commercial svnt sequential step performed first regression binary outcome continuous outcome logistic regression use receiver operating characteristic roc curve ass efficiency classification identification cut-off point euclidian index method roc curve assessment accuracy cut-off point sensitivity specificity using commercial svnts reference standard ethical declaration study approved faculty medicine chiang mai university ethic committee number approval number 311/2564 method performed accordance relevant guideline regulation